Commodore Capital DRUG Position
Active7-Fund ConvergenceCommodore Capital trimmed their position in BRIGHT MINDS BIOSCIENCES INC. (DRUG) in Q4 2025, holding $1.5M worth of shares across 18,851 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
DRUG is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for BMB-101 in 228 days (Nov 30, 2026), making the timing of Commodore's position particularly relevant.
About BRIGHT MINDS BIOSCIENCES INC.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Full company profile →Short Interest
7.0%
5.0 days to cover
Commodore Capital DRUG Position History
Frequently Asked Questions
Does Commodore Capital own DRUG?
Yes. As of Q4 2025, Commodore Capital holds 18,851 shares of BRIGHT MINDS BIOSCIENCES INC. (DRUG) valued at $1.5M. This data comes from their SEC 13F filing.
How many hedge funds own DRUG?
7 specialist biotech hedge funds currently hold DRUG, including Cormorant Asset Management, Driehaus Capital, Perceptive Advisors and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Commodore Capital first buy DRUG?
Commodore Capital's position in DRUG was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Commodore Capital's DRUG position increasing or decreasing?
Commodore Capital trimmed their DRUG position in the most recent quarter, reducing by 481,149 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DRUGCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Commodore CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →